UK COVID-19 vaccine substitute trial provides Moderna and Novavax injections
LONDON (Reuters) – A UK examine on using completely different COVID-19 vaccines in two-dose inoculations is being expanded to incorporate injections from Moderna and Novavax, researchers stated on Wednesday.
The trial, referred to as the Com-Cov examine, was first launched in February to find out whether or not giving a primary dose of a sort of COVID-19 injection and a second dose of one other produces an immune response nearly as good as utilizing two doses of the identical vaccine.
The concept, stated Matthew Snape, the Oxford College professor main the trial, “is to discover whether or not the a number of COVID-19 vaccines obtainable can be utilized extra flexibly.”
Britain and plenty of different nations in Europe are at present utilizing COVID-19 vaccines from AstraZeneca and Pfizer in nationwide vaccination campaigns in opposition to the coronavirus pandemic.
However reviews of very uncommon blood clots have prompted some governments – together with France and Germany – to say that the AstraZeneca vaccine ought to solely be given to sure age teams, or solely to individuals who have obtained a primary AstraZeneca vaccine dose ought to change to a unique vaccine for his or her second dose.
In a briefing on increasing the examine to incorporate Moderna and Novavax’s COVID-19 vaccines, Snape, affiliate professor of pediatrics and vaccinology at Oxford, stated he would search to recruit adults over the age of fifty who’ve obtained their first, or “prime” vaccination previously 8 to 12 weeks.
These volunteers, who can have obtained the AstraZeneca or Pfizer vaccine, will likely be randomly assigned to obtain both the identical vaccine, or the Moderna or Novavax vaccine, for a second dose.
The six new legs of the trial will every contain 175 individuals, including an extra 1,050 recruits in complete, Snape stated.
“If we are able to present that these blended schedules generate an immune response nearly as good as the usual schedules, and with no vital enhance in vaccine reactions, it’s going to probably permit extra individuals to finish their COVID-19 vaccination cycle sooner,” Rogue says. .
“It might additionally create resilience inside the system within the occasion that any of the vaccines are usually not obtainable.”
Outcomes from the unique mix trial, utilizing solely AstraZeneca and Pfizer injections, are anticipated as early as April or Could, whereas outcomes from the second part are anticipated to reach in July.
Reporting by Kate Kelland. Modifying by Mark Potter